Original Research
Published on 14 Mar 2024
DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis
in Cancer Molecular Targets and Therapeutics
![DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis](https://www.frontiersin.org/files/myhome article library/1356778/1356778_Thumb_400.jpg)
- 1,248 views
Original Research
Published on 14 Mar 2024
in Cancer Molecular Targets and Therapeutics
Case Report
Published on 14 Mar 2024
in Cancer Molecular Targets and Therapeutics
Case Report
Published on 11 Mar 2024
in Cancer Molecular Targets and Therapeutics
Review
Published on 08 Mar 2024
in Cancer Molecular Targets and Therapeutics
Mini Review
Published on 07 Mar 2024
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 07 Mar 2024
in Cancer Molecular Targets and Therapeutics
Review
Published on 06 Mar 2024
in Cancer Molecular Targets and Therapeutics
Mini Review
Published on 04 Mar 2024
in Cancer Molecular Targets and Therapeutics
Correction
Published on 29 Feb 2024
in Cancer Molecular Targets and Therapeutics
Review
Published on 28 Feb 2024
in Cancer Molecular Targets and Therapeutics
Editorial
Published on 28 Feb 2024
in Cancer Molecular Targets and Therapeutics
Systematic Review
Published on 28 Feb 2024
in Cancer Molecular Targets and Therapeutics
Review
Published on 26 Feb 2024
in Cancer Molecular Targets and Therapeutics
Mini Review
Published on 26 Feb 2024
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 26 Feb 2024
in Cancer Molecular Targets and Therapeutics
Correction
Published on 22 Feb 2024
in Cancer Molecular Targets and Therapeutics